Skip to content
DataLookout
Menu

NCT04168372

Fructose: Substrate, Stimulus, or Both?

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)

At risk: Primary completion moved at least 6 months later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 10 versions: 10 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 31, 2026 to Jun 30, 2027
    • Eligibility criteria expanded, about 13 words
    • Study completion pushed from Jul 20, 2027 to Dec 31, 2027
    • Collaborators expanded, about 10 words
  2. Notable Primary completion pushed from May 31, 2026 to Dec 31, 2026
    • Study completion pushed from Dec 20, 2026 to Jul 20, 2027
    v9
  3. Notable Primary completion date: Nov 20, 2024 to May 31, 2026
    • Trial status: Completed to Active, Not Recruiting
    • Study completion date: Nov 20, 2024 to Dec 20, 2026
    v8
  4. Minor Trial status: Active, Not Recruiting to Completed
    • Enrollment target: estimated 36 to confirmed 35
    • Primary completion date changed from estimate of Dec 2024 to Nov 20, 2024
    • Study completion date changed from estimate of Jun 2025 to Nov 20, 2024
    v7
  5. Notable Primary completion date: Jun 1, 2024 to Dec 2024
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: Dec 30, 2024 to Jun 2025
    • Site details revised
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Notable Primary completion date: Dec 1, 2023 to Jun 1, 2024
    • Study completion date: Jun 30, 2024 to Dec 30, 2024
    v5
  2. Notable Eligibility criteria expanded, about 5 words
    • Primary completion date: Sep 1, 2023 to Dec 1, 2023
    • Study completion date: Dec 30, 2023 to Jun 30, 2024
    v4
  3. Notable Primary completion date: Sep 1, 2022 to Sep 1, 2023
    • Eligibility criteria expanded, about 5 words
    • Study completion date: Dec 30, 2022 to Dec 30, 2023
    v3
  4. Notable Eligibility criteria expanded, about 3 words
    • Secondary endpoints: 5 to 9
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Hepatic fractional de novo lipogenesis in triglyceride rich lipoprotein (TRL)
Timeframe: 6 hours
Rate of appearance of UDP-glucose
Timeframe: 6 hours
Rate of appearance of blood glucose from gluconeogenesis
Timeframe: 6 hours

Secondary (9)

Serum triglyceride concentration
Serum glucose concentration
Serum lactate concentration
Serum insulin concentration
Serum free fatty acid concentration
Show 4 moreShow less
Enteral (chylomicron) fractional de novo lipogenesis (DNL)
Hepatic (VLDL) fractional de novo lipogenesis (DNL)
Extrasplanchnic fructose
Whole body fructose oxidation

Arms and interventions

High fructose meal, with fructose labelExperimental

2-13C fructose incorporated into a meal with high fructose content

High fructose meal, with pyruvate labelExperimental

2-13C pyruvate incorporated into a meal with high fructose content

Low fructose meal, with fructose labelExperimental

2-13C fructose incorporated into a meal with low fructose content

Low fructose meal, with pyruvate labelExperimental

2-13C pyruvate incorporated into a meal with low fructose content

Other: High fructose, fructose labeled meal, High fructose, pyruvate labeled meal, Low fructose, fructose labeled meal, Low fructose, pyruvate labeled meal

Sites

1 site in 1 country

  • Touro University CaliforniaVallejo, California, United States